Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Restasis

- PMLiVE

New eye indication for Allergan’s Ozurdex

EU approval extends the drug's use to diabetic macular oedema

- PMLiVE

Allergan agrees to shareholder meeting on Valeant bid

Pershing Square Capital convinces shareholders to request consultation

Allergan appoints financial head

Jim Hindman named chief financial officer

- PMLiVE

Valeant extends Allergan bid deadline to end of 2014

Acquisition saga carries on beyond original August 15 deadline

Allergan logo

Allergan sues Valeant and Pershing for insider trading

Botox manufacturer alleges hedge fund fraudulently built up stake in the company

Allergan logo

Allergan wields axe to fend off Valeant

Plans to cut 1.500 jobs in sign of independence

Allergan logo

Pershing mounts assault on Allergan board

Proposes new directors to secure Valeant takeover

Allergan logo

Allergan will start phase III DARPin trials next year

Will investigate drug in wet age-related macular degeneration

- PMLiVE

Allergan and taking a specialised approach

Pharma interview: Paul Navarre and Paul Boland talk about how the company, best known for Botox, is looking to create a culture of growth

- PMLiVE

Valeant takeover bid for Allergan turns hostile

Canadian firm goes directly to shareholders with offer

- PMLiVE

Allergan rebuffs Valeant once again

Could lead to hostile takeover bid

- PMLiVE

Valeant steps up pressure on Allergan with raised bid

Ups price yet again in attempt to acquire company behind Botox

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links